ERBB2 and gastroesophageal junction adenocarcinoma: On October 2010, the FDA granted approval for trastuzumab in combination with cisplatin and a fluoropyrimidine (capecitabine or 5-fluorouracil) for the treatment of patients with Her-2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who did not received previous treatment for metastatic disease.13 Several ongoing trials are evaluating trastuzumab in esophageal and gastric cancer as first and salvage treatment in recurrent cancer.